Literature DB >> 6307671

Mu-receptors mediate opioid cardiovascular effects at anterior hypothalamic sites through sympatho-adrenomedullary and parasympathetic pathways.

A Pfeiffer, G Feuerstein, R L Zerbe, A I Faden, I J Kopin.   

Abstract

Intracerebroventricular injections of selective opioid agonists were used to investigate the role of opiate receptor subtypes in cardiovascular function in awake rats. The mu-agonist (D-Ala2,MePhe4,Gly5-ol)enkephalin (1 nmol) caused a prolonged increase in blood pressure and an initial decrease followed by a delayed increase in heart rate. These effects were antagonized by the selective mu-antagonist beta-funaltrexamine. A selective delta-agonist (dimeric tetrapeptide enkephalin) was devoid of cardiovascular effects at 10 nmol, whereas a benzomorphan kappa-agonist MRZ caused a pressor response which was not antagonized by beta-funaltrexamine. The mechanisms by which opioids elicit cardiovascular effects were analyzed in detail by using microinjections into the anterior hypothalamic area. Low doses of enkephalin produced increases in heart rate and blood pressure. Associated elevations of plasma norepinephrine and epinephrine, but not vasopressin, suggested a stimulation of sympatho-adrenomedullary pathways. Higher doses caused increases in blood pressure but decreases in heart rate. Peripheral vagal blockade with atropine methyl nitrate caused a large sudden rise in heart rate, indicating that an increased vagal outflow counteracted the sympathetic activation. Adrenal demedullated rats displayed no tachycardia after anterior hypothalamic injection of low doses of enkephalin, whereas high dose caused pronounced bradycardia. Additional treatment of demedullated rats with the sympathetic blocker bretylium led to severe hypotension in addition to bradycardia. These data provide evidence that mu-opiate receptors primarily mediate cardiovascular effects of opiates in awake rats. At low doses, a sympathetic adrenomedullary activation occurs, whereas higher doses additionally activate parasympathetic efferents, both possibly from anterior hypothalamic sites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307671     DOI: 10.1210/endo-113-3-929

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution.

Authors:  C N May; M R Dashwood; C J Whitehead; C J Mathias
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

2.  Genetic analysis of the effects of morphine on plasma cyclic nucleotides and locomotor activity in male mice.

Authors:  T Muraki; R Kato
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

3.  Investigation of the central sites at which morphine acts to cause hypertension in conscious rabbits.

Authors:  C N May; C J Whitehead; M R Dashwood; C J Mathias
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

4.  Antagonistic effect of naloxone on the hypertensive response of intraventricularly administered histamine.

Authors:  M S Młynarska
Journal:  Agents Actions       Date:  1990-04

5.  Regional haemodynamic effects of mu-, delta-, and kappa-opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats.

Authors:  H Bachelard; M Pître
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

6.  The pressor response to central administration of beta-endorphin results from a centrally mediated increase in noradrenaline release and adrenaline secretion.

Authors:  C N May; C J Whitehead; C J Mathias
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

7.  The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain.

Authors:  X Z Khawaja; I C Green; J R Thorpe; M A Titheradge
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

8.  High-dose remifentanil increases blood pressure and heart rate mediated by sympatho-activation in conscious rats.

Authors:  Tetsuro Shirasaka; Takeshi Yano; Takato Kunitake; Isao Tsuneyoshi
Journal:  J Anesth       Date:  2012-11-07       Impact factor: 2.078

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.